HEALTHSTORY 626· JUNE 26, 2026

One Patient Has Been Granted Exclusive Access to Eli Lilly's Obesity Drug Retatrutide Through FDA Compassionate Use

The Food and Drug Administration and Eli Lilly have permitted a single individual to receive retatrutide — Lilly's highly anticipated obesity drug candidate — through the FDA's compassionate use program, according to a scoop by STAT News…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 625SpaceX Stock Slides 14%, on Pace for Third Straight Day of Losses as Post-IPO Rally Fades NEXT STORY 627 →Airwallex Raises $320 Million at $11 Billion Valuation to Build Financial Infrastructure for AI Agents

Keep reading

More from the desk.

11HEALTH

Teresa Nunes joins EpilepsyGTx as chief medical officer

A chief medical officer (the executive who owns a company's clinical strategy and translates scientific findings into decisions the broader organization can act on) has taken a new position. Teresa Nunes, who held that title at Allucent…

health1 MIN

16HEALTH

Senate contempt vote against Anthony Fauci diverts attention from China's documented obstruction of Covid-19 data

A Senate committee voted last week to hold Anthony Fauci in contempt of Congress after he invoked the Fifth Amendment, the constitutional protection against self-incrimination, during hearin

health2 MIN

36HEALTH

FDA clears Replimune's melanoma drug Tudriqev after two rejections

A cancer treatment rejected twice by federal regulators has now won approval. The Food and Drug Administration granted accelerated approval to Tudriqev, a drug made by the biotech company Replimune, for patients with advanced melanoma…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk